Study of blood linear RNA nominates CD55 and DLD as early-stage biomarkers for Parkinson's disease
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is the second leading neurodegenerative disease, pathologically characterized by the accumulation of alpha-synuclein in the brain and the loss of dopaminergic neurons in the substantia nigra pars compacta. Despite the intensive efforts to identify diagnostic biomarkers for PD and nominating prospective candidates such as such as CSF α-synuclein seed amplification assay or α-/β-synuclein ratio, establishment of minimally invasive biomarkers remains the focus of PD research. We leveraged transcriptomic data from 4343 participants from four independent datasets to robustly identify PD-associated transcripts. Following the differential abundance analyses, we integrated our findings with several brain transcriptomic, CSF proteomic, plasma proteomic and genomic data to add biological context. We further leveraged our findings to develop predictive models that could differentiate between PD and healthy controls. We identified 296 differentially expressed transcripts, 28 of which were transcribed from known PD-associated loci. Furthermore, we found a significant overlap between our findings and transcripts dysregulated in brain, as well as proteins that differentially accumulate in CSF. Our results suggested that expression of the identified transcripts was affected by genetic background, including ancestry and PD-related mutations, and nearly half of the identified transcripts were dysregulated before symptom onset. The differentially expressed transcripts were utilized to develop three predictive models that distinguished PD from healthy controls with an area under the receiver operating characteristic curve of 0.727–0.733. The predictive models detected transcriptomic PD signatures even before symptom onset. Overall, two transcripts, DLD and CD55, showed particular promise as early stage, minimally invasive PD biomarkers. DLD was significantly related to PD in the expression quantitative trait loci (eQTL) analyses, and we identified a putative eQTL for CD55. Their protein products differentially accumulated in CSF, and both DLD and CD55 were included in all three predictive models. Having performed the largest transcriptomic study of PD to date, we demonstrate that the transcriptome can be leveraged to develop minimally invasive biomarkers that may aid in diagnosing the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709 · cited 1×
“26 Alignment quality was assessed via Picard metrics (v2.”
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259 · cited 1×
“We performed pathway analyses on the differentially expressed genes identified in the meta-analysis using the ClusterProfiler 33 and DOSE 34 packages.”
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
Second-generation PLINK: rising to the challenge of larger and richer datasets
Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M., & Lee, J. J. (2015) · Gigascience · doi:10.1186/s13742-015-0047-8 · Cited by 12,709 · cited 1×
“41 To account for potential confounding factors, all analyses were adjusted by age, sex and gen-etic principal components one through five.”
Salmon provides fast and bias-aware quantification of transcript expression
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017) · Nature Methods · doi:10.1038/nmeth.4197 · Cited by 12,700
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
mediation:R Package for Causal Mediation Analysis
Tingley, D., Yamamoto, T., Hirose, K., Keele, L., & Imai, K. (2014) · Journal of Statistical Software · doi:10.18637/jss.v059.i05 · Cited by 4,155 · cited 1×
“To compare our results to PD GWAS, all lead single nucleotide polymorphism (SNP) coordinates were converted from the hg19 to hg38 version of the human genome.”
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Nalls, M. A., Blauwendraat, C., Vallerga, C. L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia, D. A., Noyce, A. J., Xue, A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30320-5 · Cited by 2,454 · cited 1×
“11,12 Further supporting the utility of blood-based analysis, Irmady et al .”
The Parkinson Progression Marker Initiative (PPMI)
Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.005 · Cited by 1,892
DOSE: an R/Bioconductor package for disease ontology semantic and enrichment analysis
Yu, G., Wang, L.-G., Yan, G.-R., & He, Q.-Y. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu684 · Cited by 1,274 · cited 1×
“…of the differentially expressed transcripts identified here, or, in other words, to infer causality between PD and the differentially expressed transcripts, we used summary-data-based MR 34 to test for association between the expression level of a gene and PD genetic risk using the latest PD GWAS.”
The Parkinson Pandemic—A Call to Action
Dorsey, E. R., & Bloem, B. R. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3299 · Cited by 1,091
Parkinson’s Disease in Women and Men: What’s the Difference?
Cerri, S., Mus, L., & Blandini, F. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191683 · Cited by 800
Ou, Z., Pan, J., Tang, S., Duan, D., Yu, D., Nong, H., & Wang, Z. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.776847 · Cited by 729
Siderowf, A., Concha-Marambio, L., Lafontant, D.-E., Farris, C. M., Ma, Y., Urenia, P. A., Nguyen, H., Alcalay, R. N., Chahine, L. M., Foroud, T., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00109-6 · Cited by 719 · cited 1×
“While recent studies have proposed some promising PD biomarker candidates, such as the CSF α -syn seed amplification assay, 15 identification of abnormal α -syn in skin biopsies and α -/ β -syn ratio, 16 identification of non-invasive PD biomarkers remains paramount, as it would greatly aid disease…”
Liew, C.-C., Ma, J., Tang, H.-C., Zheng, R., & Dempsey, A. A. (2006) · Journal of Laboratory and Clinical Medicine · doi:10.1016/j.lab.2005.10.005 · Cited by 660
Microglia mediate forgetting via complement-dependent synaptic elimination
Wang, C., Yue, H., Hu, Z., Shen, Y., Ma, J., Li, J., Wang, X.-D., Wang, L., Sun, B., Shi, P., et al. (2020) · Science · doi:10.1126/science.aaz2288 · Cited by 629 · cited 1×
“79 Furthermore, research by Wang et al. 80 highlights a broader role for CD55 in modulating the complement system, particularly through its inhibition of the C1q-dependent complement pathway.”
Arnesen, T., Van Damme, P., Polevoda, B., Helsens, K., Evjenth, R., Colaert, N., Varhaug, J. E., Vandekerckhove, J., Lillehaug, J. R., Sherman, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901931106 · Cited by 539
Molecular markers of early Parkinson's disease based on gene expression in blood
Scherzer, C. R., Eklund, A. C., Morse, L. J., Liao, Z., Locascio, J. J., Fefer, D., Schwarzschild, M. A., Schlossmacher, M. G., Hauser, M. A., Vance, J. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610204104 · Cited by 512 · cited 1×
“To our knowledge, this represents the largest and most comprehensive PD transcriptomic analysis to date, 11,13,45-48 encompassing data from 2628 participants across the PDBP, PPMI, BioFIND and WashU-MDC, while also addressing distinct PD subpopulations and multi-omic data integration.”
RNA-seq: impact of RNA degradation on transcript quantification
Gallego Romero, I., Pai, A. A., Tung, J., & Gilad, Y. (2014) · BMC Biology · doi:10.1186/1741-7007-12-42 · Cited by 475
Qi, T., Wu, Y., Zeng, J., Zhang, F., Xue, A., Jiang, L., Zhu, Z., Kemper, K., Yengo, L., Zheng, Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04558-1 · Cited by 427
Gibson, G. E., Sheu, K.-F. R., Blass, J. P., Baker, A., Carlson, K. C., Harding, B., & Perrino, P. (1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520320022009 · Cited by 424
Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain
Sorbi, S., Bird, E. D., & Blass, J. P. (1983) · Annals of Neurology · doi:10.1002/ana.410130116 · Cited by 396
Sturm, G., Finotello, F., & List, M. (2020) · Methods in Molecular Biology · doi:10.1007/978-1-0716-0327-7_16 · Cited by 328
Mullen, J. R., Kayne, P. S., Moerschell, R. P., Tsunasawa, S., Gribskov, M., Colavito-Shepanski, M., Grunstein, M., Sherman, F., & Sternglanz, R. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb03615.x · Cited by 323
Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease
Kim, J. J., Vitale, D., Otani, D. V., Lian, M. M., Heilbron, K., the 23andMe Research Team, Aslibekyan, S., Auton, A., Babalola, E., Bell, R. K., et al. (2024) · Nature Genetics · doi:10.1038/s41588-023-01584-8 · Cited by 285 · cited 15×
“Notably, 2 of the 28 transcripts, STAT3 and QRICH1 , scored an eight in the PD GWAS locus browser, 39 comparable to the well-established PD gene GBA1 , which has a score of nine.”
InfluentialBlood–brain barrier leakage is increased in parkinson’s disease
Al-Bachari, S., Naish, J. H., Parker, G. J. M., Emsley, H. C. A., & Parkes, L. M. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.593026 · Cited by 263 · cited 12×
“To assess their relationship with PD, we conducted two-sample MR using summary statistics from the latest PD GWAS, which revealed 13 regions nominally associated with PD. Eleven of the thirteen regions had already been identified by the latest PD GWAS.”
InfluentialAn immunohistochemical study on α‐ketoglutarate dehydrogenase complex in Parkinson's disease
Mizuno, Y., Matuda, S., Yoshino, H., Mori, H., Hattori, N., & Ikebe, S. (1994) · Annals of Neurology · doi:10.1002/ana.410350212 · Cited by 199
Identification and characterization of the human ARD1–NATH protein acetyltransferase complex
ARNESEN, T., ANDERSON, D., BALDERSHEIM, C., LANOTTE, M., VARHAUG, J. E., & LILLEHAUG, J. R. (2005) · Biochemical Journal · doi:10.1042/bj20041071 · Cited by 194
Bellinger, F. P., Bellinger, M. T., Seale, L. A., Takemoto, A. S., Raman, A. V., Miki, T., Manning-Boğ, A. B., Berry, M. J., White, L. R., & Ross, G. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-8 · Cited by 173
Power, J. H. T., & Blumbergs, P. C. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0438-3 · Cited by 171 · cited 12×
“Elevated PROC levels have been linked to a decreased risk of dementia, 70 while SCLY mediates selenoprotein turnover, which is disrupted in PD. 71-73 Furthermore, we found that 80 of the 296 differentially expressed transcripts in blood were also differentially expressed in brain, supporting the…”
InfluentialmultiGSEA: a GSEA-based pathway enrichment analysis for multi-omics data
(2020) · doi:10.1186/s12859-020-03910-x · Cited by 170 · cited 1×
“14.0) 35 package to calculate the combined P -value via Fisher’s combined probability test.”
InfluentialDifferential meta-analysis of RNA-seq data from multiple studies
Rau, A., Marot, G., & Jaffrézic, F. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-91 · Cited by 170 · cited 1×
“20 Briefly, we aligned the raw reads to the human genome reference (GRCh38) and annotated transcripts with Gencode 33 annotation using STAR (v2.”
Multi-modality machine learning predicting Parkinson’s disease
Makarious, M. B., Leonard, H. L., Vitale, D., Iwaki, H., Sargent, L., Dadu, A., Violich, I., Hutchins, E., Saffo, D., Bandres-Ciga, S., et al. (2022) · npj Parkinson's Disease · doi:10.1038/s41531-022-00288-w · Cited by 158
Analysis of blood-based gene expression in idiopathic Parkinson disease
Shamir, R., Klein, C., Amar, D., Vollstedt, E., von Bonin, M., Usenovic, M., Wong, Y. C., Maver, A., Poths, S., Safer, H. M., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004516 · Cited by 149 · cited 1×
“Unlike previous studies, 14,48 we used two independent cohorts to validate our models, showing that they maintained similar levels of accuracy in the validation populations.”
A review of genome‐wide transcriptomics studies in Parkinson's disease
Borrageiro, G., Haylett, W. L., Seedat, S., Kuivaniemi, H., & Bardien, S. (2017) · European Journal of Neuroscience · doi:10.1111/ejn.13760 · Cited by 124 · cited 1×
“10 For instance, a study measuring differences in blood RNA expression data identified and validated eight genes associated with PD risk from a recent meta-analysis of genome-wide association studies (GWAS).”
Craig, D. W., Hutchins, E. D., Violich, I., Alsop, E. B., Gibbs, J. R., Levy, S. A., Robison, M., Prasad, N., Foroud, T., Crawford, K. L., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00088-6 · Cited by 114 · cited 4×
“11,20,24,25 The publicly available datasets, PDBP, PPMI and BioFIND, were accessed through the Accelerating Medicines Partnership Parkinson’s Disease (AMP-PD) Knowledge Portal.”
InfluentialThe NINDS Parkinson's disease biomarkers program
Rosenthal, L. S., Drake, D., Alcalay, R. N., Babcock, D., Bowman, F. D., Chen‐Plotkin, A., Dawson, T. M., Dewey, R. B., German, D. C., Huang, X., et al. (2016) · Movement Disorders · doi:10.1002/mds.26438 · Cited by 111 · cited 1×
“11,20,24,25 The publicly available datasets, PDBP, PPMI and BioFIND, were accessed through the Accelerating Medicines Partnership Parkinson’s Disease (AMP-PD) Knowledge Portal.”
Loss of amino-terminal acetylation suppresses a prion phenotype by modulating global protein folding
Holmes, W. M., Mannakee, B. K., Gutenkunst, R. N., & Serio, T. R. (2014) · Nature Communications · doi:10.1038/ncomms5383 · Cited by 109
Molecular Signatures of Neuroinflammation Induced by αSynuclein Aggregates in Microglial Cells
Sarkar, S., Dammer, E. B., Malovic, E., Olsen, A. L., Raza, S. A., Gao, T., Xiao, H., Oliver, D. L., Duong, D., Joers, V., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00033 · Cited by 93 · cited 9×
“This study also included symptomatic participants with mutations in LRRK2 , GBA1 and SNCA, as well as asymptomatic individuals at high risk for PD, such as LRRK2 and GBA1 mutation carriers or those with RBD or hyposmia.”
InfluentialImpaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease
Mytilineou, C., Werner, P., Molinari, S., Rocco, A. D., Cohen, G., & Yahr, M. D. (1994) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02260943 · Cited by 92
The Parkinson's Disease Genome‐Wide Association Study Locus Browser
Grenn, F. P., Kim, J. J., Makarious, M. B., Iwaki, H., Illarionova, A., Brolin, K., Kluss, J. H., Schumacher‐Schuh, A. F., Leonard, H., Faghri, F., et al. (2020) · Movement Disorders · doi:10.1002/mds.28197 · Cited by 92 · cited 4×
“Finally, we browsed the PD GWAS locus browser 39 and recorded the scores, which rank genes based on the level of support, for those genes that overlapped PD-associated loci.”
InfluentialLiu, Z., Yan, M., Liang, Y., Liu, M., Zhang, K., Shao, D., Jiang, R., Li, L., Wang, C., Nussenzveig, D. R., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.018 · Cited by 89 · cited 2×
“…Olig2, a key transcription factor, and interacts with the nucleoporin Seh1 to regulate oligodendrocyte differentiation and myelination in the CNS. 83 This interaction is important for maintaining proper neural function, and myelination defects are common in neurodegenerative diseases, including…”
Raychaudhuri, S., Sinha, M., Mukhopadhyay, D., & Bhattacharyya, N. P. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddm301 · Cited by 86
Irmady, K., Hale, C. R., Qadri, R., Fak, J. J., Simelane, S., Carroll, T., Przedborski, S., & Darnell, R. B. (2023) · Nature Communications · doi:10.1038/s41467-023-39652-6 · Cited by 86 · cited 2×
“13 identified 1584 transcripts that were significantly dysregulated in PD blood and showed similar changes in expression within the caudate and putamen regions of the PD brain.”
Wang, C., Chen, L., Yang, Y., Zhang, M., & Wong, G. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0621-5 · Cited by 82
Changes in Selenoprotein P in Substantia Nigra and Putamen in Parkinson's Disease
Bellinger, F. P., Raman, A. V., Rueli, R. H., Bellinger, M. T., Dewing, A. S. T., Seale, L. A., Andres, M. A., Uyehara‐Lock, J. H., White, L. R., Ross, G. W., et al. (2012) · Journal of Parkinson s Disease · doi:10.3233/jpd-2012-11052 · Cited by 79 · cited 12×
“Elevated PROC levels have been linked to a decreased risk of dementia, 70 while SCLY mediates selenoprotein turnover, which is disrupted in PD. 71-73 Furthermore, we found that 80 of the 296 differentially expressed transcripts in blood were also differentially expressed in brain, supporting the…”
InfluentialChen, V., Moncalvo, M., Tringali, D., Tagliafierro, L., Sriskanda, A., Ilich, E., Dong, W., Kantor, B., & Chiba‐Falek, O. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa183 · Cited by 77 · cited 1×
“49-51 Furthermore, our analysis suggested that expression differences are influenced by ethnic background, highlighting the need for multi-ancestry approaches in PD research.”
Nucleo–cytoplasmic transport defects and protein aggregates in neurodegeneration
Bitetto, G., & Fonzo, A. D. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00205-2 · Cited by 74
Gibson, G. E., Chen, H.-L., Xu, H., Qiu, L., Xu, Z., Denton, T. T., & Shi, Q. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.11.003 · Cited by 69 · cited 1×
“85 87-92 This points to a possible connection between impaired energy metabolism and neurodegeneration.”
Shi, Q., Xu, H., Kleinman, W. A., & Gibson, G. E. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2007.12.008 · Cited by 66
Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease
Kelly, J., Moyeed, R., Carroll, C., Albani, D., & Li, X. (2019) · Molecular Brain · doi:10.1186/s13041-019-0436-5 · Cited by 65 · cited 1×
“79 Furthermore, research by Wang et al. 80 highlights a broader role for CD55 in modulating the complement system, particularly through its inhibition of the C1q-dependent complement pathway.”
Parkinson’s Disease Biomarkers: Perspective from the NINDS Parkinson’s Disease Biomarkers Program
Gwinn, K., David, K. K., Swanson-Fischer, C., Albin, R., Hillaire-Clarke, C. S., Sieber, B.-A., Lungu, C., Bowman, F. D., Alcalay, R. N., Babcock, D., et al. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0370 · Cited by 64 · cited 1×
“11,20,24,25 The publicly available datasets, PDBP, PPMI and BioFIND, were accessed through the Accelerating Medicines Partnership Parkinson’s Disease (AMP-PD) Knowledge Portal.”
The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort
Kang, U. J., Goldman, J. G., Alcalay, R. N., Xie, T., Tuite, P., Henchcliffe, C., Hogarth, P., Amara, A. W., Frank, S., Rudolph, A., et al. (2016) · Movement Disorders · doi:10.1002/mds.26613 · Cited by 63
Common X‐Chromosome Variants Are Associated with Parkinson Disease Risk
Le Guen, Y., Napolioni, V., Belloy, M. E., Yu, E., Krohn, L., Ruskey, J. A., Gan‐Or, Z., Kennedy, G., Eger, S. J., & Greicius, M. D. (2021) · Annals of Neurology · doi:10.1002/ana.26051 · Cited by 57 · cited 3×
“37,38,44 Eight of these transcripts were also differentially expressed in brain, adding evidence to their involvement in PD, while the blood-specific transcripts could be contributing to other, non-neuronal, aspects of the disease pathophysiology.”
InfluentialDysregulation of mitochondrial and proteolysosomal genes in Parkinson’s disease myeloid cells
Navarro, E., Udine, E., Lopes, K. D. P., Parks, M., Riboldi, G., Schilder, B. M., Humphrey, J., Snijders, G. J. L., Vialle, R. A., Zhuang, M., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00110-x · Cited by 57 · cited 1×
“77 In fact, protein products of 9 of the 296 differentially expressed transcripts ( CD55 , DLD , MGAT4B , MTPAP , NPLOC4 , PDGFD , PLXNC1 , POR and PSMD5 ) differentially accumulated in CSF, six with the same direction of effect in blood and CSF, further validating the relevance of our blood…”
Zhao, R., Liu, Y., Wang, H., Yang, J., Niu, W., Fan, S., Xiong, W., Ma, J., Li, X., Phillips, J. B., et al. (2016) · Cellular and Molecular Immunology · doi:10.1038/cmi.2016.31 · Cited by 54
β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein
Li, X., Yu, L., Liu, X., Shi, T., Zhang, Y., Xiao, Y., Wang, C., Song, L., Li, N., Liu, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53086-8 · Cited by 50 · cited 1×
“…proposed some promising PD biomarker candidates, such as the CSF α -syn seed amplification assay, 15 identification of abnormal α -syn in skin biopsies and α -/ β -syn ratio, 16 identification of non-invasive PD biomarkers remains paramount, as it would greatly aid disease diagnosis and monitoring.”
Defining the limits: Protein aggregation and toxicity in vivo
Holmes, W. M., Klaips, C. L., & Serio, T. R. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2014.914151 · Cited by 49
Fernández, M. V., Liu, M., Beric, A., Johnson, M., Cetin, A., Patel, M. R., Budde, J., Kohlfeld, P., Bergmann, K., Lowery, J., et al. (2024) · Scientific Data · doi:10.1038/s41597-024-03485-9 · Cited by 49 · cited 2×
“11,20,24,25 The publicly available datasets, PDBP, PPMI and BioFIND, were accessed through the Accelerating Medicines Partnership Parkinson’s Disease (AMP-PD) Knowledge Portal.”
Self-citationAmyloid-associated activity contributes to the severity and toxicity of a prion phenotype
Pezza, J. A., Villali, J., Sindi, S., & Serio, T. R. (2014) · Nature Communications · doi:10.1038/ncomms5384 · Cited by 47
Asaumi, M. (2005) · The Journal of Biochemistry · doi:10.1093/jb/mvi014 · Cited by 44
Ahmad, W., & Ebert, P. R. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.08.004 · Cited by 44
Lee, Y., Cho, J.-H., Lee, S., Lee, W., Chang, S., Chung, H. Y., Moon, H. R., & Lee, J. (2018) · Brain Research · doi:10.1016/j.brainres.2018.09.036 · Cited by 40 · cited 12×
“To assess their relationship with PD, we conducted two-sample MR using summary statistics from the latest PD GWAS, which revealed 13 regions nominally associated with PD. Eleven of the thirteen regions had already been identified by the latest PD GWAS.”
InfluentialHastings, A. F., Cullinane, P. W., Wrigley, S., Révész, T., Morris, H. R., Dickson, J. C., Jaunmuktane, Z., Warner, T. T., & Pablo‐Fernández, E. D. (2024) · Neurology · doi:10.1212/wnl.0000000000209453 · Cited by 38 · cited 1×
“54,55 Furthermore, cost, accessibility and radiation exposure present substantial practical constraints to neuroimaging approaches.”
Exome Sequencing and the Identification of New Genes and Shared Mechanisms in Polymicrogyria
Akula, S. K., Chen, A. Y., Neil, J. E., Shao, D. D., Mo, A., Hylton, N. K., DiTroia, S., Ganesh, V. S., Smith, R. S., O’Kane, K., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.2363 · Cited by 37
Evaluation of RNA Blood Biomarkers in the Parkinson’s Disease Biomarkers Program
Santiago, J. A., Bottero, V., & Potashkin, J. A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00157 · Cited by 33
Yao, H., Tong, W., Song, Y., Li, R., Xiang, X., Cheng, W., Zhou, Y., He, Y., Yang, Y., Liu, Y., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03234-0 · Cited by 33 · cited 1×
“78 CD55, also known as decay-accelerating factor (DAF), inhibits the complement cascade, which has been implicated in the pathogenesis of PD through its association with α -syn and Lewy bodies.”
Pérez-Segura, I., Santiago-Balmaseda, A., Rodríguez-Hernández, L. D., Morales-Martínez, A., Martínez-Becerril, H. A., Martínez-Gómez, P. A., Delgado-Minjares, K. M., Salinas‐Lara, C., Martínez-Dávila, I. A., Guerra‐Crespo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043264 · Cited by 32 · cited 1×
“…PD. 74 These transcripts were also enriched in the PPAR signalling pathway, a potential therapeutic target with neuro-protective effects in PD. 75,76 The downregulation of PSMD5 , a pro-teolysosomal gene, which was dysregulated at both the transcript level in blood and protein level in CSF, has…”
Xu, Y., Cao, W., Zhou, M., Li, C.-Q., Luo, Y., Wang, H., Zhao, R., Jiang, S., Yang, J., Liu, Y., et al. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.02.031 · Cited by 31 · cited 1×
“Inactivation of BRD7 in animal models impairs cognitive behaviour and reduces synaptic plasticity, particularly in the mPFC. 81 Additionally, BRD7 plays an anti-inflammatory role by inhibiting the NF-κ B signalling pathway, a key pathway involved in neuroinflammation.”
Choudhury, K. R., & Bhattacharyya, N. P. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.11.035 · Cited by 30
Early-stage idiopathic Parkinson’s disease is associated with reduced circular RNA expression
Whittle, B. J., Izuogu, O. G., Lowes, H., Deen, D., Pyle, A., Coxhead, J., Lawson, R. A., Yarnall, A. J., Jackson, M. S., Santibanez‐Koref, M., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00636-y · Cited by 26 · cited 1×
“Instead of using baseline, as previous studies 11,21 have done for cross-sectional analyses, we selected the last assessment of each participant to maximize the clinical and molecular differences between cases and controls and harmonize with the BioFIND and WashU-MDC co-horts’ inclusion criteria.”
Parkinson's disease biomarkers program brain imaging repository
Ofori, E., Du, G., Babcock, D., Huang, X., & Vaillancourt, D. E. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.05.005 · Cited by 25
Brown, A. M., Gordon, D., Lee, H., Vrièze, F. W., Cellini, E., Bagnoli, S., Nacmias, B., Sorbi, S., Hardy, J., & Blass, J. P. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9235-3 · Cited by 22
RNA Nucleocytoplasmic Transport Defects in Neurodegenerative Diseases
Boehringer, A. V., & Bowser, R. P. (2018) · Advances in neurobiology · doi:10.1007/978-3-319-89689-2_4 · Cited by 22
Ghosh, B., Karmakar, S., Prasad, M., & Mandal, A. K. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e20-11-0747 · Cited by 22 · cited 1×
“67,68 Together, these findings suggest that PJA1 plays a broad protective role in suppressing protein aggregation and mitigating neurodegenerative processes.”
Watabe, K., Niida‐Kawaguchi, M., Tada, M., Kato, Y., Murata, M., Tanji, K., Wakabayashi, K., Yamada, M., Kakita, A., & Shibata, N. (2022) · Neuropathology · doi:10.1111/neup.12840 · Cited by 21 · cited 1×
“67,68 Together, these findings suggest that PJA1 plays a broad protective role in suppressing protein aggregation and mitigating neurodegenerative processes.”
Beric, A., Sun, Y.-C., Sanchez, S., Martin, C., Powell, T., Kumar, R., Pardo, J. A., Darekar, G., Sanford, J., Dikec, D., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00839-3 · Cited by 21
Self-citationAlpha-synuclein seeding amplification assays in Lewy body dementia: a brief review
Bregendahl, M. E., Kaya, Z. B., Singer, W., & McLean, P. J. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00868-3 · Cited by 17 · cited 1×
“52,53 Advanced neuroimaging performs well at differentiating between PD and healthy controls, with studies reporting perfect sensitivity (100%), but the specificity seems to be highly varied and dependent on the imaging technology, being as low as 53% in some reports.”
Cell-free RNA signatures predict Alzheimer’s disease
Cisterna‐García, A., Beric, A., Ali, M., Pardo, J. A., Chen, H., Fernández, M. V., Norton, J. B., Gentsch, J., Bergmann, K., Budde, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108534 · Cited by 14 · cited 1×
“We leveraged differentially expressed transcripts and a previously established pipeline 9,42 to construct predictive models.”
Self-citationDiagnostic accuracy of cerebral [18F]FDG PET in atypical parkinsonism
Houssein, N. J., Henriksen, A. C., Hejl, A., & Marner, L. (2023) · EJNMMI Research · doi:10.1186/s13550-023-01025-x · Cited by 14 · cited 1×
“54,55 Furthermore, cost, accessibility and radiation exposure present substantial practical constraints to neuroimaging approaches.”
STAT3 protects dopaminergic neurons against degeneration in animal model of Parkinson's disease
Smit, R. D., Ghosh, B., Campion, T., Stingel, R. L., Lavell, E., Hooper, R., Fan, X., Soboloff, J., & Smith, G. M. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148691 · Cited by 14 · cited 1×
“56 Despite not being significant in the MR analyses, we found significant correlation between STAT3 and clinical measures of motor signs (UPDRS-III) and cognitive decline (MoCA), providing further support for the involvement of STAT3 .”
Xin, G., Niu, J., Tian, Q., Fu, Y., Chen, L., Yi, T., Tian, K., Sun, X.-S., Wang, N., Wang, J., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0294984 · Cited by 11 · cited 1×
“84 On top of that, analyses stratified by mutation carrier status revealed that the association be-tween DLD expression and PD is primarily driven by PD-related mutations, with further evidence indicating that the expression of DLD in at-risk participants is already altered prior to symptom onset.”
Tin, A., Walker, K. A., Bressler, J., Windham, B. G., Griswold, M. E., Sullivan, K., Wu, A., Gottesman, R. F., Fornage, M., Coresh, J., et al. (2021) · Neuroepidemiology · doi:10.1159/000516287 · Cited by 9 · cited 1×
“Elevated PROC levels have been linked to a decreased risk of dementia, 70 while SCLY mediates selenoprotein turnover, which is disrupted in PD. 71-73 Furthermore, we found that 80 of the 296 differentially expressed transcripts in blood were also differentially expressed in brain, supporting the…”
Kuang, Y., Mao, H., Dai, W. H., Gan, T., Lin, H., Li, S., Yang, X., & Xu, P. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00488-3 · Cited by 8 · cited 1×
“52,53 Advanced neuroimaging performs well at differentiating between PD and healthy controls, with studies reporting perfect sensitivity (100%), but the specificity seems to be highly varied and dependent on the imaging technology, being as low as 53% in some reports.”
Beric, A., Cisterna‐García, A., Martin, C., Kumar, R., Alfradique‐Dunham, I., Boyer, K., Saliu, I. O., Yamada, S., Sanford, J., Western, D., et al. (2024) · medRxiv · doi:10.1101/2024.10.18.24315717 · Cited by 3 · cited 2×
“We leveraged differentially expressed transcripts and a previously established pipeline 9,42 to construct predictive models.”
Self-citation
Research works printed but not linked: 1
- Nalls, 2019, Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: A meta-analysis of genome-wide association studies, Lancet Neurol, 18, 1091, 10.1016/S1474-4422(19)30320-5 · DOI · Paper page
Cited by
Wu, J., Zhang, Q., & Zang, W. (2026) · Sensors · doi:10.3390/s26061853
“Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by degeneration of the nigrostriatal dopaminergic pathway, with cardinal clinical features including bradykinesia, rigidity, and resting tremor [1,2].”
Holzhausen, F., Spitzenberg, C., Pauly, D., & Baeumner, A. J. (2026) · Talanta · doi:10.1016/j.talanta.2026.130079
Metadata
- Authors
- Beric, A., Sahin, S., Sanchez, S., Yang, Z., Kumar, R., Alfradique-Dunham, I., Sanford, J., Western, D., Phillips, B., Budde, J. P., Perrin, R. J., Kotzbauer, P. T., Perlmutter, J. S., Norris, S. A., Cruchaga, C., & Ibanez, L.
- Affiliations
- Washington University in St. Louis (US)
- Department of Neurology, Washington University in Saint Louis School of Medicine , St.Louis, MO 63110 ,
- Department of Psychiatry, Washington University in Saint Louis School of Medicine , St.Louis, MO 63110 ,
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2026-01-13
- Volume
- 149
- Issue
- 10
- Pages
- 3509-3523
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC13584185
- OpenAlex
- W7123868984
- Cited by
- 2
- References
- 85
- Citations by year
- 2026: 2
- FWCI
- 8.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
- Funders
- Department of Defense (W81XWH2010849)
- Bright Focus Foundation (A2021033S)
- Michael J. Fox Foundation (MJFF-021599)
- National Institutes of Health (P30AG066444, R00AG062723, U19AG03243812, R01AG053267, RF1NS075321)
- Alzheimer’s Association (DIAN-TU-PP-22-872356, DIANTUOLE21725093)
- American Parkinson Disease Association
- the Barnes-Jewish Hospital Foundation
- Paula and Rodger Riney Fund
- NGI Pilot Grant
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Parkinson's disease, blood transcriptome, CD55, DLD, minimally invasive biomarkers, differential gene expression, CSF proteomics, plasma proteomics, genetic ancestry, genetic variants, prediction model, alpha-synuclein, expression quantitative trait loci
- MeSH terms
- Aged, Female, Humans, Male, Middle Aged, Parkinson Disease, RNA, Biomarkers, CD55 Antigens, Proteomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.